A single-arm, single-centre, observational study to assess the efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold System by CT angiogram in patients with coronary artery disease.

This is a prospective, single-arm, single-centre study to evaluate the CT angiographic outcomes after implantation of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in patients with coronary artery disease. The objective of this study is to assess vessel patency, luminal dimensions, and presence of in-scaffold obstruction using CT angiography after MeRes100 BRS implantation. The safety and efficacy of MeRes100 BRS has been previously established in the MeRes-1 and MeRes-1 Extend trials, which reported sustained safety and clinical performance up to three years. Two-year outcomes showed favourable angiographic results with a low rate of target lesion failure and no definite or probable scaffold thrombosis. CT angiography has demonstrated good diagnostic accuracy in detecting in-scaffold luminal obstruction and measuring luminal dimensions post implantation. Studies suggest that CT angiography and conventional coronary angiography offer similar diagnostic accuracy in identifying obstructive coronary artery disease. Therefore, this study aims to further evaluate CT angiographic outcomes in patients treated with MeRes100 BRS.